The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV : results from the EuroSIDA study
© 2021 British HIV Association..
OBJECTIVES: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH).
METHODS: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
RESULTS: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
CONCLUSIONS: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
HIV medicine - 23(2022), 6 vom: 04. Juli, Seite 585-598 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mocroft, Amanda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA, Viral |
|---|
| Anmerkungen: |
Date Completed 09.06.2022 Date Revised 25.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13210 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334255694 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334255694 | ||
| 003 | DE-627 | ||
| 005 | 20231225223326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13210 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334255694 | ||
| 035 | |a (NLM)34889022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mocroft, Amanda |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV |b results from the EuroSIDA study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2022 | ||
| 500 | |a Date Revised 25.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 British HIV Association. | ||
| 520 | |a OBJECTIVES: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH) | ||
| 520 | |a METHODS: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit | ||
| 520 | |a RESULTS: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer | ||
| 520 | |a CONCLUSIONS: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HBV DNA | |
| 650 | 4 | |a hepatitis B | |
| 650 | 4 | |a nonliver cancer | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 700 | 1 | |a Miro, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Wandeler, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Llibre, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a van Bremen, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Beniowski, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Mikhalik, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Cavassini, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Maltez, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Duvivier, Claudine |e verfasserin |4 aut | |
| 700 | 1 | |a Uberti Foppa, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Knysz, Brygida |e verfasserin |4 aut | |
| 700 | 1 | |a Bakowska, Elzbieta |e verfasserin |4 aut | |
| 700 | 1 | |a Kuzovatova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo, Pere |e verfasserin |4 aut | |
| 700 | 1 | |a Zagalo, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Viard, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Degen, Olaf |e verfasserin |4 aut | |
| 700 | 1 | |a Milinkovic, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Benfield, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Lars |e verfasserin |4 aut | |
| 700 | 0 | |a EuroSIDA study group |e verfasserin |4 aut | |
| 700 | 1 | |a Harxhi, A |e investigator |4 oth | |
| 700 | 1 | |a Losso, M |e investigator |4 oth | |
| 700 | 1 | |a Kundro, M |e investigator |4 oth | |
| 700 | 1 | |a Schmied, B |e investigator |4 oth | |
| 700 | 1 | |a Zangerle, R |e investigator |4 oth | |
| 700 | 1 | |a Karpov, I |e investigator |4 oth | |
| 700 | 1 | |a Vassilenko, A |e investigator |4 oth | |
| 700 | 1 | |a Mitsura, V M |e investigator |4 oth | |
| 700 | 1 | |a Paduto, D |e investigator |4 oth | |
| 700 | 1 | |a Clumeck, N |e investigator |4 oth | |
| 700 | 1 | |a De Wit, S |e investigator |4 oth | |
| 700 | 1 | |a Delforge, M |e investigator |4 oth | |
| 700 | 1 | |a Florence, E |e investigator |4 oth | |
| 700 | 1 | |a Vandekerckhove, L |e investigator |4 oth | |
| 700 | 1 | |a Hadziosmanovic, V |e investigator |4 oth | |
| 700 | 1 | |a Begovac, J |e investigator |4 oth | |
| 700 | 1 | |a Machala, L |e investigator |4 oth | |
| 700 | 1 | |a Sedlacek, D |e investigator |4 oth | |
| 700 | 1 | |a Kronborg, G |e investigator |4 oth | |
| 700 | 1 | |a Gerstoft, J |e investigator |4 oth | |
| 700 | 1 | |a Katzenstein, T |e investigator |4 oth | |
| 700 | 1 | |a Pedersen, C |e investigator |4 oth | |
| 700 | 1 | |a Johansen, I S |e investigator |4 oth | |
| 700 | 1 | |a Ostergaard, L |e investigator |4 oth | |
| 700 | 1 | |a Wiese, L |e investigator |4 oth | |
| 700 | 1 | |a Moller, N F |e investigator |4 oth | |
| 700 | 1 | |a Nielsen, L N |e investigator |4 oth | |
| 700 | 1 | |a Zilmer, K |e investigator |4 oth | |
| 700 | 1 | |a Smidt, J |e investigator |4 oth | |
| 700 | 1 | |a Aho, I |e investigator |4 oth | |
| 700 | 1 | |a Lacombe, K |e investigator |4 oth | |
| 700 | 1 | |a Pradier, C |e investigator |4 oth | |
| 700 | 1 | |a Fontas, E |e investigator |4 oth | |
| 700 | 1 | |a Rockstroh, J |e investigator |4 oth | |
| 700 | 1 | |a Behrens, G |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, C |e investigator |4 oth | |
| 700 | 1 | |a Stellbrink, H J |e investigator |4 oth | |
| 700 | 1 | |a Stefan, C |e investigator |4 oth | |
| 700 | 1 | |a Bogner, J |e investigator |4 oth | |
| 700 | 1 | |a Fätkenheuer, G |e investigator |4 oth | |
| 700 | 1 | |a Chkhartishvili, N |e investigator |4 oth | |
| 700 | 1 | |a Sambatakou, H |e investigator |4 oth | |
| 700 | 1 | |a Adamis, G |e investigator |4 oth | |
| 700 | 1 | |a Paissios, N |e investigator |4 oth | |
| 700 | 1 | |a Szlávik, J |e investigator |4 oth | |
| 700 | 1 | |a Gottfredsson, M |e investigator |4 oth | |
| 700 | 1 | |a Devitt, E |e investigator |4 oth | |
| 700 | 1 | |a Tau, L |e investigator |4 oth | |
| 700 | 1 | |a Turner, D |e investigator |4 oth | |
| 700 | 1 | |a Burke, M |e investigator |4 oth | |
| 700 | 1 | |a Shahar, E |e investigator |4 oth | |
| 700 | 1 | |a Wattad, L M |e investigator |4 oth | |
| 700 | 1 | |a Elinav, H |e investigator |4 oth | |
| 700 | 1 | |a Haouzi, M |e investigator |4 oth | |
| 700 | 1 | |a Elbirt, D |e investigator |4 oth | |
| 700 | 1 | |a D'Arminio Monforte, A |e investigator |4 oth | |
| 700 | 1 | |a Esposito, R |e investigator |4 oth | |
| 700 | 1 | |a Mazeu, I |e investigator |4 oth | |
| 700 | 1 | |a Mussini, C |e investigator |4 oth | |
| 700 | 1 | |a Mazzotta, F |e investigator |4 oth | |
| 700 | 1 | |a Gabbuti, A |e investigator |4 oth | |
| 700 | 1 | |a Lazzarin, A |e investigator |4 oth | |
| 700 | 1 | |a Castagna, A |e investigator |4 oth | |
| 700 | 1 | |a Gianotti, N |e investigator |4 oth | |
| 700 | 1 | |a Galli, M |e investigator |4 oth | |
| 700 | 1 | |a Ridolfo, A |e investigator |4 oth | |
| 700 | 1 | |a Uzdaviniene, V |e investigator |4 oth | |
| 700 | 1 | |a Matulionyte, R |e investigator |4 oth | |
| 700 | 1 | |a Staub, T |e investigator |4 oth | |
| 700 | 1 | |a Hemmer, R |e investigator |4 oth | |
| 700 | 1 | |a Dragas, S |e investigator |4 oth | |
| 700 | 1 | |a Stevanovic, M |e investigator |4 oth | |
| 700 | 1 | |a Vd Valk, M |e investigator |4 oth | |
| 700 | 1 | |a Trajanovska, J |e investigator |4 oth | |
| 700 | 1 | |a Reikvam, D H |e investigator |4 oth | |
| 700 | 1 | |a Maeland, A |e investigator |4 oth | |
| 700 | 1 | |a Bruun, J |e investigator |4 oth | |
| 700 | 1 | |a Szetela, B |e investigator |4 oth | |
| 700 | 1 | |a Inglot, M |e investigator |4 oth | |
| 700 | 1 | |a Flisiak, R |e investigator |4 oth | |
| 700 | 1 | |a Grzeszczuk, A |e investigator |4 oth | |
| 700 | 1 | |a Parczewski, M |e investigator |4 oth | |
| 700 | 1 | |a Maciejewska, K |e investigator |4 oth | |
| 700 | 1 | |a Aksak-Was, B |e investigator |4 oth | |
| 700 | 1 | |a Mularska, E |e investigator |4 oth | |
| 700 | 1 | |a Jablonowska, E |e investigator |4 oth | |
| 700 | 1 | |a Kamerys, J |e investigator |4 oth | |
| 700 | 1 | |a Wojcik, K |e investigator |4 oth | |
| 700 | 1 | |a Mozer-Lisewska, I |e investigator |4 oth | |
| 700 | 1 | |a Rozplochowski, B |e investigator |4 oth | |
| 700 | 1 | |a Mansinho, K |e investigator |4 oth | |
| 700 | 1 | |a Radoi, R |e investigator |4 oth | |
| 700 | 1 | |a Oprea, C |e investigator |4 oth | |
| 700 | 1 | |a Gusev, D |e investigator |4 oth | |
| 700 | 1 | |a Trofimova, T |e investigator |4 oth | |
| 700 | 1 | |a Khromova, I |e investigator |4 oth | |
| 700 | 1 | |a Borodulina, E |e investigator |4 oth | |
| 700 | 1 | |a Ranin, J |e investigator |4 oth | |
| 700 | 1 | |a Tomazic, J |e investigator |4 oth | |
| 700 | 1 | |a Miró, J M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 23(2022), 6 vom: 04. Juli, Seite 585-598 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g day:04 |g month:07 |g pages:585-598 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13210 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 6 |b 04 |c 07 |h 585-598 | ||